Targeting IL-18 was found to be effective in experimental models of autoimmune diseases including inflammatory bowel disease (50) and rheumatoid arthritis (51), as well as to be safe in clinical patients (52). This evidence concerns the gene IL18 and inflammatory bowel disease.